12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Inavir laninamivir: Completed Phase III enrollment

Biota said Daiichi Sankyo completed enrollment in a double-blind, placebo-controlled, Japanese Phase III trial evaluating 2 doses of Inavir laninamivir in about 1,500 healthy family members of...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >